References
- Smolen JS, Aletaha D, McInnes IB. et al.
Rheumatoid
arthritis. The Lancet 2016;388 :2023-38.
- Scott DL, Wolfe F, Huizinga TW. Rheumatoid arthritis. The Lancet
2010;376 :1094-108.
- Favalli EG, Biggioggero M, Meroni PL. Methotrexate for the treatment
of rheumatoid arthritis in the biologic era: still an ‘anchor’ drug?
Autoimmun Rev 2014;13 :1102-8.
- Cantini F, Nannini C, Niccoli L et al.
Guidance for the
management of patients with latent tuberculosis infection requiring
biologic therapy in rheumatology and dermatology clinical practice.
Autoimmun Rev 2015;14 :503-9.
- Nimmerjahn
F,
Ravetch
JV. Fcgamma receptors as regulators of immune responses Nat Rev
Immunol . 2008;8 :34-47.
- Kaneko Y, Nimmerjahn F, Ravetch JV et al. Among authors: ravetch jv.
Anti-inflammatory
activity of immunoglobulin G resulting from Fc sialylation. Science
2006;313 :670-3.
- Hodge JA, Kawabata TT, Krishnaswami S et al.
The mechanism of
action of tofacitinib - an oral Janus kinase inhibitor for the
treatment of rheumatoid arthritis. Clin Exp Rheumatol.
2016;34 :318-28.
- Epstein O. The spatial homeostasis hypothesis // Symmetry. – 2018;10:
103.
- Dugina JL, Petrov VI, Babayeva AR et al. A randomized, open-label,
comparative, 6-month trial of oral ultra-low doses of antibodies to
tumor necrosis factor-α and diclofenac in rheumatoid arthritis //
International Journal of Tissue Reactions 2005;XXVII (1):
15-21.
- Ivana
Jovčevska , Serge
Muyldermans. The Therapeutic Potential of Nanobodies. BioDrugs
2020;34 :11-26.
- Imbach P,
Barandun
S,
d’Apuzzo
V et al. High-dose intravenous γ‑globulin for idiopathic
thrombocytopenic purpura in childhood. Lancet 1981;1 (8232):1228-31
- https://www.fda.gov/vaccines-blood-biologics/approved-blood-products/immune-globulin-intravenous-igiv-indications
- Zandman-Goddard G, Krauthammer A, Levy Y, et al. Long-term therapy
with intravenous immunoglobulin is beneficial in patients with
autoimmune diseases. Clin Rev Allergy Immunol
2012;42 :247–55.
- Katz U, Shoenfeld Y, Zandman-Goddard G. Update on intravenous
immunoglobulins (IVIg) mechanisms of action and off-label use in
autoimmune diseases. Curr Pharm Des 2011;17 :3166-75.
- Ephrem A, Misra N, Hassan G et al. Immunomodulation of autoimmune and
inflammatory diseases with intravenousimmunoglobulin. Clin Exp Med
2005 5 :135-40.
- Bayry J, Negi VS, Kaveri SV et al.
Intravenous
immunoglobulin therapy in rheumatic diseases. Nat Rev Rheumatol
2011;7 :349-59.
- Katz-Agranov N, Khattri S, Zandman-Goddard G. The role of intravenous
immunoglobulins in the treatment of rheumatoid arthritis. Autoimmun
Rev 2015 14 :651–8.
- Mulhearn B, Bruce IN.Mulhearn B, et al.
Indications for IVIG
in rheumatic diseases. Rheumatology (Oxford) 2015;54 :383-91.
- Levy Y, Sherer Y, Langevitz Pet al. Skin score decrease in systemic
sclerosis patients treated with intravenous immunoglobulin - a
preliminary report. Clin Rheumatol 2000;19 : 207-11.
- Amital H, Levy Y, Shoenfeld Y. Use of intravenous immunoglobulin in
livedo vasculitis. Clin Exp Rheumatol 2000;18 : 404-6.
- Meissner M, Sherere Y, Levy Y. Chwalinska H, Langevitz P, Shoenfeld Y.
Intravenous immunoglobulin therapy in a patient with lupus serositis
and nephritis. Rheumatol Int 2000;19 :199-201.
- Levy Y, Amital H, Langevitz P et al. Intravenous immunoglobulin
modulates cutaneous involvement and reduces skin fibrosis in systemic
sclerosis: an open-label study. Arthritis Rheumatology
2004;50 :1005-7.
- Shoenfeld Y, Krause I. IVIG for autoimmune, fibrosis, and malignant
conditions: our experience with 200 patients. J Clin Immunol
2004;24 :107-14.
- Levy Y, Sherer Y, Ahmed A et al. Autoantibody level modification in
adult patients with idiopathic thrombocytopenic purpura following
intravenous immunoglobulin treatment. Nat Immun 1998;16 :
207-24.
- Muscat C, Bertotto A, Ercolani R et al. Long term treatment of
rheumatoid arthritis with high doses of intravenous immunoglobulins:
effects on disease activity and serum cytokines. Ann Rheum Dis 1995;54 :382–5.
- Tumiati B, Casoli P, Veneziani M, Rinaldi G. High-dose immunoglobulin
therapy as an immunomodulatory treatment of rheumatoid arthritis.
Arthritis Rheumatol 1992; 35 :1126–33.
- Kazatchkine MD, and SV Kaveri. Immunomodulation of autoimmune and
inflammatory diseases with intravenous immune globulin. N Engl J Med
2001;345 :747–55.
- Kaneko Y, Nimmerjahn F, Ravetch JV et al.
Anti-inflammatory
activity of immunoglobulin G resulting from Fc sialylation. Science.
2006;313 :670-3.
- Tha-In T, Bayry J, Metselaar HJ, Kaveri SV, Kwekkeboom J.Modulation of
the cellular immune system by intravenous immunoglobulin. Trends
Immunol 2008; 29 :608–15.
- Schwab I, and F Nimmerjahn. Intravenous immunoglobulin therapy: how
does IgG modulate the immune system? Nat Rev Immunol
2013;13 :176–89.
- Washburn N, Schwab I, Ortiz D et al.
Controlled tetra-Fc
sialylation of IVIg results in a drug candidate with consistent
enhanced anti-inflammatory activity. Proc Natl Acad Sci U S A.
2015;112 :E1297-306.
- Miyoshi M, Liu S.Miyoshi M, et al.
Collagen-Induced
Arthritis Models. Methods Mol Biol. 2018;1868 :3-7
- Bashi T, Shovman O, Fridkin M et al.
Novel therapeutic
compound tuftsin-phosphorylcholine attenuates collagen-induced
arthritis. Clin Exp Immunol 2016;184 :19-28.
- Blank M, Bashi T, Lachnish J et al.
Helminths-based
bi-functional molecule, tuftsin-phosphorylcholine (TPC), ameliorates
an established murine arthritis. PLoS One. 2018;13 :e0200615.
- Svetlicky N, Kivity S, Odeh Q et al. immunoglobulin attenuates
collagen-induced arthritis in mice. Clin Exp Immunol.
2015;182 :241-50.
- Park E, Cho M, Ki CS. Correct use of repeated measures analysis of
variance. Korean J Lab Med 2009;29 :1-9..
- Gertel S, Serre G, Shoenfeld Y, Amital H. Immune tolerance induction
with multiepitope peptide derive from citrullinated autoantigens
attenuates arthritis manifestations in adjuvant arthritis rats. J
Immunol. 2015; 194: 5674-80.
- Lee SY, Jung YO, Ryu JG et al. Intravenous immunoglobulin attenuates
experimental autoimmune arthritis by inducing reciprocal regulation of
Th17 and Treg cells in an interleukin-10-dependent manner. Arthritis
Rheumatol 2014; 66 :1768-7.
- Christensen AD, Haase C, Cook AD, Hamilton JA. K/BxN serum-transfer
arthritis as a model for human inflammatory arthritis. Front Immunol
2016;7 :213-7.
- Lewis BJB, Ville J, Blacquiere M, et al.
Using the K/BxN mouse
model of endogenous, chronic, rheumatoid arthritis for the evaluation
of potential immunoglobulin-based therapeutic agents, including IVIg
and Fc-μTP-L309C, a recombinant IgG1 Fc hexamer. BMC Immunol
2019;20:44-54.
- Le Pottier L, Sapir T, Bendaoud B, Youinou P, Shoenfeld Y, Pers JO.
Itravenous immunoglobulin and cytokines. Focus on tumor necrosis
factor family members BAFF and APRIL. Ann NY Acad Sci
2007;1110 : 426-32.
- Sherer Y, Wu R, Krause I et al.
Cytokine levels in
various intravenous immunoglobulin (IVIg) preparations. Hum
Antibodies 2001;10:51-3.
- Bendtzen K, Hansen MB, Ross C et al. Stem Cells.
Cytokines and
autoantibodies to cytokines 1995;13 :206-22.
- Cervera R, Rodríguez-Pintó I, Espinosa G.Cervera R, et al.
The diagnosis and
clinical management of the catastrophic antiphospholipid syndrome: A
comprehensive review. J Autoimmun 2018;92 :1-11.
- Liu Q, Zhou YH, Yang ZQ et al.
The cytokine storm of
severe influenza and development of immunomodulatory therapy. Cell
Mol Immunol 2016;13 :3-10.
- Davey RT Jr, Fernבndez-Cruz E, Markowitz N et al. Anti-influenza
hyperimmune intravenous immunoglobulin for adults with influenza A or
B infection (FLU-IVIG):a double-blind, randomised, placebo-controlled
trial. Lancet Respir Med 2019;7 : 951–63.
- Mehta P, McAuley DF, Brown M et al. COVID-19: consider cytokine storm
syndromes and immunosuppression. Lancet 2020;395 :1033-4.
- Soy M, Keser G, Atagündüz P, Tabak F, Atagündüz I, Kayhan S.
Cytokine storm in
COVID-19: pathogenesis and overview of anti-inflammatory agents used
in treatment. Clin Rheumatol 2020;39 :2085-94.
- Domínguez-Soto Á, Simón-Fuentes M, de Las Casas-Engel M et al.
IVIg Promote
Cross-Tolerance against Inflammatory Stimuli In Vitro and In Vivo. J
Immunol 2018;201 :41-52.
- Ohmi Y, Ise W, Harazono A, Takakura D et al. Sialylation converts
arthritogenic IgG into inhibitors of collagen-induced arthritis. Nat
Commun 2016;7 :11025-37.
- Campbell IK, Miescher S, Branch DR et al.
Therapeutic effect
of IVIG on inflammatory arthritis in mice is dependent on the Fc
portion and independent of sialylation or basophils. J Immunol
2014;192 :5031-8.